Biological markers of Alzheimer's disease

Drug Development Research

Volumn 56, Issue 2, 2002, Pages 74-84

  Mehta, Pankaj D ^a   Pirttilä, Tuula ^b  

^a NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Alzheimer's disease; Amyloid beta protein; Biomarkers; Diagnosis; Tau protein

Indexed keywords

AD7C PROTEIN; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BIOCHEMICAL MARKER; BIOLOGICAL MARKER; IRON BINDING PROTEIN; NEURONAL THREAD PROTEIN; PROTEIN P97; TAU PROTEIN; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; ANAMNESIS; BEHAVIOR; BRAIN CORTEX; CEREBROSPINAL FLUID ANALYSIS; COGNITION; DEGENERATIVE DISEASE; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DISEASE COURSE; FAMILY HISTORY; HUMAN; LABORATORY TEST; NEUROFIBRILLARY TANGLE; NEUROPSYCHOLOGICAL TEST; PHYSICAL EXAMINATION; REVIEW; RISK FACTOR;

EID: 0036599163     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10063     Document Type: Review

References (115)

1. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: A community based follow up study
2. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: Differences between early- and late-onset Alzheimer disease and stability during the course of disease
3. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample
4. Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment
5. Evaluation for CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice
6. Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's disease
7. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology
8. Platelet APP isoform ratios correlate with declining cognition in AD
9. Tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer disease?
10. Cerebrospinal fluid tau levels increase with age in healthy individuals
11. Staging of Alzheimer's disease-related neurofibrillary changes
12. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid
13. Platelets are the primary source of amyloid β-peptide in human blood
14. Detection of amyloid beta protein precursor immunoreactivity in normal and Alzheimer disease
15. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer disease in late onset families
16. Profiles of neuronal thread protein expression in Alzheimer disease
17. Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease
18. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype
19. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: Differential expression of tau protein mRNAs in human brain
20. Dependence of cerebrospinal fluid tau protein levels on apolipoprotein E4 allele frequency in patients with Alzheimer's disease
21. Incorporating biomarkers into clinical drug trials in Alzheimer disease
22. Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease
23. Analysis and quantitation of APP in the CSF of Alzheimer disease patients with a monoclonal antibody based immunoassay
24. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after stroke
25. Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients. An ultra bienzyme-substrate-recycle enzyme-linked immunosorbent assay
26. Improved discrimination of AD patients using betaamyloid(1-42) and tau levels in CSF
27. Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay
28. Tau immuno reactivity detected in human plasma, but not increased in Alzheimer disease
29. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease
30. Tau proteins in cerebrospinal fluid from patients with Alzheimer's disease: A longitudinal study
31. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease
32. Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression
33. Quantification of Alzheimer amyloid β peptides ending at residues 40 and 42 by novel ELISA systems
34. The tau protein in human cerebrospinal fluid in Alzheimer's disease consists of proteolytically derived fragments
35. Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF
36. Longitudinal study of cerebrospinal fluid levels of tau, Abeta 1-40, and Abeta 1-42(43) in Alzheimer's disease: A study in Japan
37. Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies
38. Highly increased CSF tau protein and decreased β-amyloid (1-42) in sporadic CJD: A discrimination from Alzheimer's disease?
39. Serum levels of the iron binding protein p97 are elevated in Alzheimer disease
40. Serum melanotransferrin, p97 as a biochemical marker for Alzheimer disease
41. Determination of amyloid β protein precursors harboring active form of proteinase inhibitor domains in cerebrospinal fluid of Alzheimer's disease patients by trypsin-antibody sandwich ELISA
42. Detection of tau phosphorylated at threonien 231 in cerebrospinal fluid of Alzheimer's disease patients
43. The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta42(43)
44. Tau in situ hybridization in normal and Alzheimer brain: Localization in the somatodendritic compartment
45. Tau protein in cerebrospinal fluid is significantly increased at the earliest clinical stage of Alzheimer disease
46. Neuropathological correlates to clinically defined dementia with Lewy bodies
47. Functional implications for the microtubule-associated protein tau: Localization in oligodendrocytes
48. Microtubule associated protein tau epitopes are present in fiber lesions in diverse muscle disorders
49. Passage of human amyloid beta-protein 1-40 across the murine blood-brain barrier
50. Cerebrospinal fluid amyloid β1-42 levels in the mild cognitive impairment stage of Alzheimer's disease
51. Tau-like immunoreactivity in Alzheimer and control skin fibroblasts
52. Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease
53. Clinical diagnosis of Alzheimer disease: Report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer disease
54. Tau protein in cerebrospinal fluid: A new diagnostic and prognostic marker in Alzheimer disease?
55. Increased plasma amyloid beta protein 1-42 levels in Down syndrome
56. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease
57. Tau and apoE in CSF: Potential aid for discriminating Alzheimer's disease from other dementias
58. Reduction of beta-amyloid peptide 42 in the cerebrospinal fluid of patients with Alzheimer's disease
59. Tau protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease
60. Amyloid β protein levels in cerebrospinal fluid are elevated in early-onset Alzheimer's disease
61. Basic and clinical studies on the measurement of tau protein in cerebrospinal fluid as a biological marker for Alzheimer's disease and related disorders: Multicenter study in Japan
62. Cerebrospinal fluid levels of amyloid b-protein in Alzheimer's disease: Inverse correlation with severity of dementia and effect of apolipoprotein E genotype
63. Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease
64. Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease
65. Soluble derivatives of the β amyloid protein precursor in cerebrospinal fluid: Alterations in normal aging and in Alzheimer's disease
66. Tau protein immunoreactivity in dementia of the Alzheimer type. I. Morphology, evolution, distribution, and pathogenetic implications
67. For the Phospho-Tau international study group CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies
68. Mild cognitive impairment
69. Soluble amyloid β-protein in the cerebrospinal fluid from patients with Alzheimer's disease, vascular dementia and controls
70. Cerebrospinal fluid concentrations of soluble amyloid beta-protein and apolipoprotein E in patients with Alzheimer's disease: Correlations with amyloid load in the brain
71. Ischemic rats as a model in the study of the neurobiological role of human beta-amyloid peptide. Timedependent disappearing diffuse amyloid plaques in brain
72. Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions
73. Diagnosis, management and treatment of Alzheimer disease
74. Cerebrospinal protein tau is elevated in early Alzheimer's disease
75. Cerebrospinal beta-amyloid (1-42) in early Alzheimer's disease: Association with apolipoprotein E genotype and cognitive decline
76. Altered amyloid protein processing in platelets of patients with Alzheimer disease
77. CSF beta-amyloid, cognition, and APOE genotype in Alzheimer's disease
78. Association of apolipoprotein E allele ε4 with late onset familial and sporadic Alzheimer disease
79. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
80. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease
81. Cerebral changes and cerebrospinal fluid beta-amyloid in Alzheimer's disease: A study with quantitative magnetic resonance imaging
82. Extracellular and cerebrospinal fluids
83. Normal and abnormal biology of the β-amyloid precursor protein
84. Isolation and quantitation of soluble Alzheimer's Aβ-peptide from biological fluids
85. Combination assay of CSF tau, Aβ1-40 and Aβ1-42(43) as a biochemical marker of Alzheimer's disease
86. CSF levels of tau, β-amyloid 1-42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging
87. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD
88. Tau and Aβ42 in cerebrospinal fluid from healthy adults 21-93 years of age: Establishment of reference values
89. Both total and phhosphorylated tau are increased in Alzheimer's disease
90. Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced disparate mechanisms
91. Diagnosis and treatment of Alzheimer disease and related disorders
92. Assessment of amyloid beta protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease
93. Longitudinal stability of CSF tau levels in Alzheimer patients
94. Tau protein in cerebrospinal fluid (CSF): A blood-CSF barrier related evaluation in patients with various neurological diseases
95. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants
96. Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease
97. Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease
98. Amyloid beta protein species in cerebrospinal fluid and in brain from patients with Down's syndrome
99. A genetic dichotomy model for the inheritance of Alzheimer disease and common age-related disorders
100. The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease
101. CSF tau is related to apoE genotype in early Alzheimer's disease
102. Three-year follow-up of cerebrospinal fluid tau, β-amyloid 42 and 40 concentrations in Alzheimer's disease
103. Relationship between apoE genotype and CSF β-amyloid (1-42) and tau in patients with probable and definite Alzheimer's disease
104. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay
105. Concentrations of amyloid β protein in cerebrospinal fluid of patients with Alzheimer's disease
106. Decreased levels of soluble amyloid β-protein precursor in cerebrospinal fluid of live Alzheimer disease patients
107. Standardization of measurement of β-amyloid(1-42) in cerebrospinal fluid and plasma
108. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: A sandwich ELISA with a synthetic phosphopeptide for standardization
109. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease
110. Cerebral amyloid angiopathy: Amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease
111. The neuropathology of Alzheimer's disease
112. Alzheimer-related neuronal protein A68: Specificity and distribution
113. Evidence that Aβ42 is the real culprit in Alzheimer disease
114. Quantification of axonal damage in traumatic brain injury: Affinity purification and characterization of cerebrospinal fluid tau proteins
115. Blood-brain barrier transport of circulating Alzheimer's amyloid β